Issam Saleh Alghamdi, MD in Allston, MA - Internal Medicine

Issam Saleh Alghamdi, MD is a Internal Medicine physician based in Allston, Massachusetts. Issam Saleh Alghamdi is licensed to practice in Massachusetts (license number 239680) and his current practice location is 119 Brainerd Rd, Apt 11, Allston, Massachusetts. He can be reached at his office (for appointments etc.) via phone at (857) 383-0832.

NPI number for Issam Saleh Alghamdi is 1114252582 and his current mailing address is 119 Brainerd Rd, Apt 11, Allston, Massachusetts. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1114252582.

Contact Information

	Issam Saleh Alghamdi, MD
	119 Brainerd Rd, Apt 11, Allston, MA 02134-3732
	(857) 383-0832
	Not Available

Physician's Profile

Full Name	Issam Saleh Alghamdi
Gender	Male
Speciality	Internal Medicine
Location	119 Brainerd Rd, Allston, Massachusetts
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1114252582
Provider Enumeration Date: 10/02/2009
Last Update Date: 10/02/2009

Medical Identifiers

Medical identifiers for Issam Saleh Alghamdi such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1114252582	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207R00000X	Internal Medicine	239680 (Massachusetts)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Issam Saleh Alghamdi is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Issam Saleh Alghamdi, MD 119 Brainerd Rd, Apt 11, Allston, MA 02134-3732 Ph: (857) 383-0832	Issam Saleh Alghamdi, MD 119 Brainerd Rd, Apt 11, Allston, MA 02134-3732 Ph: (857) 383-0832

News Archive

VCU Gastroenterology research papers ranked 4th in most cited papers

Virginia Commonwealth University's School of Medicine has been ranked fourth among federally funded U.S. universities based on the average number of citations per research paper published in indexed journals of gastroenterology and hepatology between 1999 and 2003.

Findings show how cancer and aging are tightly interconnected

Researchers from the Geisel School of Medicine at Dartmouth have found that epigenetic changes to DNA are associated with aging in disease-free breast tissues and are further altered in breast tumors. Epigenetic changes describe heritable alterations caused by mechanisms other than by changes in DNA sequence. The discovery, published in the February 2014 issue of Epigenetics, illustrates how cancer and aging are tightly interconnected processes by identifying epigenetic alterations present in the normal aging breast that may increase disease risk in cancer-free individuals.

Feasible to create a stockpile of H5N1 vaccine

Countries and vaccine manufacturers agreed on Wednesday in a meeting at WHO that it may be feasible to create a stockpile of H5N1 vaccine, and to separately develop a mechanism to ensure broader access to pandemic influenza vaccine for developing countries in the advent of a pandemic.

Study reveals that most Americans will refuse FDA authorized emergency use H1N1 flu vaccine

A majority of Americans would not take an H1N1 flu vaccine or drug additive authorized for emergency use by the Food and Drug Administration, according to a University of Pittsburgh Graduate School of Public Health and University of Georgia study. The study, available online today in Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science, found that fewer than 10 percent of those surveyed said they would be willing to take such a vaccine or drug and nearly 30 percent remained undecided.

Sanofi's Lyxumia achieves primary efficacy endpoint in study of patients uncontrolled on metformin

Sanofi announced today that Lyxumia (lixisenatide), a once-daily GLP-1 receptor agonist under development for type 2 diabetes, achieved its primary efficacy endpoint of significant HbA1c reduction vs. placebo in patients uncontrolled on metformin.

Internal Medicine Doctors in Allston, MA

Hussein Kekhia, Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 235 Harvard Ave, Allston, MA 02134 Phone: 617-678-2016
Alicia S Romero, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 14 Everett St, Apt. #1, Allston, MA 02134 Phone: 617-208-8618

Issam Saleh Alghamdi, MD - Internal Medicine in Allston, MA